Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
Список исп. литературыСкрыть список 1. Allgulander C et al. Venlafaxine extended release (ER) in the treatment of generalized anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179: 15–22. 2. Allgulander C et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004; 161: 1642–9. 3. Allgulander C et al. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006; 9: 495–505. 4. Baldwin D et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol 2005; 19: 567–96. 5. Baldwin D et al. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 2006; 189: 264–72. 6. Baldwin D et al. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 2007; 41 (10): 1583–92. 7. Baldwin D et al. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 2007; 3 (2): 185–91. 8. Baldwin D et al. Antipsychotic drugs in the treatment of generalized anxiety disorder. Int Journal of Psychiatry in Clin Pract 2009, 13, SII. 9. Baldwin D et al. Does early improvement predict endpoint response in patients with generalized anxiety disorder treated with pregabalin or venlafaxine XR? Eur Neuropsychopharmacol 2011; 22 (2): 137–1342. 10. Baldwin D et al. Evidence-based pharmacotherapy of generalized anxiety disorder. Essential Evidence-based psychopharmacology. Cambridge University Press, 2013; p. 112–4. 11. Bandelow B et al. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry 2007; 8 (3): 175–87. 12. Bandelow B, Zohar J et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry 2008; 9 (4): 248–312. 13. Bandelow B et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010; 13 (3): 305–20. 14. Beekman AT et al. Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry 1998; 13 (10): 717–26. 15. Beesdo K et al. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatr Clin North Am 2009; 32 (3): 483–524. 16. Bodkin JA et al. Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder. Hum Psychopharmacol 2011; 26 (3): 258–66. 17. Brawman-Mintzer O et al. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005, 66: 1321–5. 18. Brawman-Mintzer O et al. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67 (6): 874–81. 19. Bruce SE et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005; 162 (6): 1179–87. 20. Carney CE et al. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatry 2007; 68 (2): 254–60. 21. Chessick CA et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; 19 (3): CD006115. 22. Davidson JR et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Neuropsychopharmacol 2008; 18 (9): 673–81. 23. Diagnostic and statistical manual of mental disorders. 5th ed. Text revision (DSM-5). Washington, DC: American Psychiatric Press, 2013. 24. Feltner DE et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23 (3): 240–9. 25. Feltner DE et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008; 23 (1): 18–28. 26. Goodman WK et al. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005; 87 (2–3): 161–67. 27. Hartford J et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active controlled trial. Int Clin Psychopharmacol 2007; 22: 167–74. 28. Hidalgo RB et al. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007; 21: 864–72. 29. Hunot V et al. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev 2007; 24 (1): CD001848. 30. Judd L, Kessler RC. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study. Acta Psychiatr Scand Suppl 1998; 393: 6–11. 31. Kasper S et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009; 24 (2): 87–96. 32. Katzman M et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011; 26 (1): 11–24. 33. Khan A et al. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 2011; 31 (4): 418–28. 34. Laakmann G et al. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl) 1998; 136 (4): 357–66. 35. Lenox-Smith AJ et al. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract 2003; 53: 772–7. 36. Lenze EJ et al. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA 2009; 301 (3): 295–303. 37. Leonardo E. Anxiety as a developmental disorder. Neuropsychopharmacology 2008; 33 (1): 134–40. 38. Levinson-Castiel R et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160 (2): 173–6. 39. Martin JLR et al. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol 2007; 21 (7): 774–82. 40. Mezhebovsky I et al. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry 2013; 28 (6): 615–25. 41. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005; 88: 27–45. 42. Montgomery SA et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67: 771–82. 43. Munk-Jorgensen P et al. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland and Norway. Psychiatr Serv 2006; 57 (12): 1738–44. 44. Nutt D, Sharpe M. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacol 2008; 22: 3–6. 45. Pande AC et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160: 533–40. 46. Perugi G et al. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response. Neuropsychobiology 2002; 46 (3): 145–9. 47. Pinheiro et al. Psychiatric morbidity and alcohol use by pregnant women in a public obstetric service. Rev Saude Publica 2005; 39 (4): 593–8. 48. Pohl RB et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25: 151–8. 49. Pollack MH et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62 (5): 350–7. 50. Pollack MH et al. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol 2003; 23 (3): 250–9. 51. Pollack MH et al. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res 2008; 42 (14): 1176–84. 52. Rickels K et al. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50: 884–95. 53. Rickels K et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157: 968–74. 54. Rickels K et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 749–56. 55. Rickels K et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022–30. 56. Rickels K et al. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 2006; 67 (1): 41–7. 57. Rickels K et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol 2012; 27 (3): 142–50. 58. Rodriguez BF et al. Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis 2006; 194 (2): 91–7. 59. Rynn M et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008; 25 (3): 182–9. 60. Stein DJ et al. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry 2005; 17 (2): 71–5. 61. Stein DJ et al. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28 (5): 561–6. 62. Stein DJ et al. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008; 18 (6): 422–30. 63. Stocchi F et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder J Clin Psychiatry 2003; 64 (3): 250–8. 64. Tyrer P et al. The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med 2004; 34 (8): 1385–94. 65. Whalen PJ et al. A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Biol Psychiatry 2008; 63 (9): 858–63. 66. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002; 16: 162–71.